Expert Review of Anticancer Therapy

Second-line chemotherapy in head and neck cancer: what should we expect?
pp. 269-273(5)
Authors: Büntzel, Jens; Micke, Oliver

Cancer stem cells and the cell cycle: targeting the drive behind breast cancer
pp. 275-279(5)
Authors: Velasco-Velázquez, Marco A; Yu, Zuoren; Jiao, Xuanmao; Pestell, Richard G

News in brief
pp. 281-283(3)

New approved dasatinib regimen available for clinical use
pp. 285-292(8)
Author: Snyder, David S

Concurrent chemotherapy and radiotherapy for head and neck cancer
pp. 293-302(10)
Authors: Burri, Ryan J; Lee, Nancy Y

Treatment of Barrett's esophagus with high-grade dysplasia
pp. 303-316(14)
Authors: McAllaster, Jennifer D; Buckles, Daniel; Al-Kasspooles, Mazin

Contemporary management of papillary carcinoma of the thyroid gland
pp. 317-329(13)
Authors: Rosenbaum, Michael A; McHenry, Christopher R

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
pp. 331-356(26)
Authors: Webb, Thomas R; Slavish, Jake; George, Rani E; Look, A Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B; Morris, Stephan W

Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand
pp. 357-363(7)
Authors: Visani, Giuseppe; Isidori, Alessandro

T-cell prolymphocytic leukemia
pp. 365-371(7)
Authors: Khot, Amit; Dearden, Claire

Recent advances in the systemic treatment of metastatic papillary renal cancer
pp. 373-379(7)
Authors: Chowdhury, Simon; Choueiri, Toni K

Acknowledgements
pp. 385-385(1)

Erratum
pp. 388-388(1)